Humanis Brings Digital Innovation to Pulmonary Hypertension: PAHCase

Humanis, a leading pharmaceutical and healthcare company, introduced PAHCase, a digital case platform developed for physicians working in pulmonary vascular disease, at the 8th Pulmonary Vascular Disease Meeting held on 21-24 May. PAHCase provides physicians with the opportunity to review case simulations close to real clinical practice and evaluate their own cases with physicians from different specialties within a closed consultation structure.

Humanis launched the PAHCase digital platform with healthcare professionals, developed to strengthen knowledge sharing and multidisciplinary collaboration in the field of pulmonary vascular disease. Designed through case examples reflecting real clinical practice, the platform supports physicians' faster and sustainable access to scientific content while contributing to case-based evaluation processes.

"With PAHCase, We Offer Our Physicians an Interactive Expertise Network"
Dr. Yalçın Yaşin, General Manager of Commercial Operations at Humanis, stated that the platform presents an innovative structure that strengthens scientific interaction among physicians:

"Pulmonary vascular diseases are among important disease groups requiring multidisciplinary evaluation in diagnosis and treatment processes. With Humanis PAHCase, we offer our physicians an interactive expertise network that supports scientific sharing, experience transfer and shared evaluation culture. We regard this project, which has no counterpart in field implementation and physician communication, as an important step that increases scientific interaction, supports case-based evaluation and contributes to sustainable knowledge sharing. We believe that PAHCase will present a new approach in terms of digitalization and scientific communication in the pulmonary hypertension field."

Digital Platform Supporting Clinical Practice
Through the PAHCase platform, physicians can access case simulations reflecting real clinical practice, review interactive content related to diagnosis and treatment processes, and benefit from evaluations of expert physicians. Additionally, users have the opportunity to transfer their own cases to closed consultation groups to receive expert opinion.

The platform aims to share scientific content focused on Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), differential diagnosis processes, multidisciplinary patient management, current treatment approaches and case discussions.

About Humanis
Humanis, which began operations in 2010 under Saya Group as Pharmactive, has continued its work under the Humanis brand since 2023. Operating with the understanding of "sustainable healthcare for all," the company makes important contributions to the Turkish pharmaceutical sector through its manufacturing facility and research and development center established in Çerkezköy with a USD 200 million investment.

Humanis, which carries out manufacturing partnerships with leading pharmaceutical companies worldwide, operates in many different therapeutic areas including pediatrics, cardiology, pulmonology, otorhinolaryngology, internal medicine, infectious diseases, gastroenterology, dermatology, physical therapy and rehabilitation, orthopedics, rare diseases, psychiatry and neurology. The company continues its human-centered and innovative healthcare approach through its consumer health products.